Researchers discover method to halt breast cancer spread

A Major Breakthrough in Breast Cancer Research

Scientists have made a significant advancement in the treatment of breast cancer by targeting the mechanisms that allow the disease to spread throughout the body. This breakthrough centers on the removal of specific building blocks that enable cancer to metastasize, offering new hope for patients and medical professionals alike.

Cancer has a way of altering the metabolism of immune cells, leading them to release a substance known as uracil. This metabolite plays a crucial role in helping distant organs create a "scaffold" that supports the growth of secondary tumors. By blocking the enzyme called uridine phosphorylase-1 (UPP1), which is responsible for producing uracil, researchers were able to prevent this scaffold from forming in mice. This intervention restored the immune system's ability to attack secondary cancer cells, effectively stopping the spread of the disease.

The research was carried out in the laboratories of Professor Jim Norman and Professor Karen Blyth at the Cancer Research UK Scotland Institute and the University of Glasgow. Their findings open up new possibilities for tackling cancer, including the potential to detect uracil in the blood as an early indicator of cancer spread. Once detected, drugs that block UPP1 could be used to halt the spread before it begins.

Dr. Cassie Clarke, the lead researcher on the study, emphasized the importance of this discovery. She stated, “This study represents a major shift in how we think about preventing the spread of breast cancer. By targeting these metabolic changes as early as possible, we could stop the cancer progressing and save lives.”

The research, published in the journal Embo Reports, highlights key metabolic changes that occur in the body before cancer spreads. These changes offer a critical window for intervention. Detecting such changes early could allow for therapies that prevent cancer cells from traveling through the body and forming new tumors elsewhere.

Dr. Catherine Elliott, Director of Research at Cancer Research UK, noted the progress made in treating breast cancer. She said, “Discoveries in cancer research have made breast cancer a far more treatable disease than ever before. However, metastasis—when cancer spreads—is a major factor in breast cancer becoming harder to treat, especially if the cancer returns months or even many years later. This discovery gives us new hope for detecting and stopping metastasis early and ensuring people have many more years with their families and loved ones.”

In the United Kingdom, approximately 56,800 people are diagnosed with breast cancer each year, and around 11,300 people lose their lives to the disease annually. Finding new ways to combat breast cancer is essential, as while the disease has become more treatable due to research, it becomes significantly harder to manage once it spreads to other parts of the body.

Understanding the mechanisms behind how breast cancer spreads is vital for developing strategies to prevent the disease from becoming unmanageable with current treatments. The research team is now focusing on further investigating how UPP1 affects the behavior of immune cells. They are also exploring the role of immune cell metabolism in the early stages of breast cancer and testing drugs that can block this process to prevent cancer from occurring.

Simon Vincent, chief scientific officer at Breast Cancer Now, described the research as exciting and impactful. He stated, “This is an exciting piece of joint research that expands our understanding of how secondary breast cancer develops. The researchers discovered that high levels of a protein called UPP1 may make some cancers, including breast cancer, more likely to spread to other parts of the body, where the disease becomes incurable. In mice, targeting the UPP1 protein before secondary breast cancer developed led to fewer secondary breast tumors and a boosted immune response in the lungs.”

With around 61,000 people living with secondary breast cancer in the UK, research like this is crucial. Further studies are needed to determine whether this insight can be translated into new drugs that stop secondary breast cancer and potentially other forms of secondary cancer in their tracks.